Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Notice of Annual General Meeting: November 9

181010_Notice of Annual Meeting

Category: News & Announcements 2018By Richard Mollard October 10, 2018

Related posts

Top 20 Shareholders 30th December 2018
January 7, 2019

Top 20 Shareholders 14 December 2018
December 17, 2018

PharmAust Manufacturing Method Maintains Drug Potency
December 2, 2018

GMP Tablet Production for Clinical Trials Commences
November 13, 2018

2018 AGM Results
November 9, 2018

2018 AGM Presentation
November 9, 2018

Recent Articles

200921_PharmAust Awarded FightMND Grant for Phase I Trial
September 21, 2020
14 September, Shareholder Update
September 14, 2020
Elanco not to Exercise Agreed Option
September 9, 2020
Monepantel Anti-Covid-19 Activity Confirmed
September 9, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

Brad Turner @turnerMNDlab·

Exciting news about a world-first trial of monepantel for #MND #ALS in Australia. https://twitter.com/pharmaust/status/1307832264269598720

PharmAust@PharmAust

PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease https://smallcaps.com.au/pharmaust-fightmnd-monepantel-phase-one-trial-motor-neuron-disease/ via @SmallCapsASX

Reply on Twitter 1307873727913193474 Retweet on Twitter 13078737279131934742 Like on Twitter 130787372791319347410 Twitter 1307873727913193474

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions